In March, the FDA approved Janssen Pharmaceuticals’ depression drug esketamine, a form of...
Janssen’s esketamine nasal spray not recommended by NICE for NHS use
The UK’s pricing regulator the National Institute for Health and Clinical Excellence (NICE) has decided to not recommend Janssen’s Spravato (esketamine) nasal spray in combination with an oral antidepressant for adults with treatment-resistant major depressive disorder for routine National Health Service (NHS) use.
FDA greenlight for esketamine sheds light on ketamine’s potential
In March, the FDA approved Janssen Pharmaceuticals’ depression drug esketamine, a form of ketamine for use as a treatment for depression. Billed as the most exciting antidepressant in decades, the drug has an entirely new mechanism of action. So what does esketamine offer, and why is the FDA so sure the benefits outweigh the risks?
Cost-effectiveness could affect the uptake of Spravato for the treatment of MDD
Spravato is estimated to cost $198,000 per quality-adjusted life year (QALY) gained, exceeding the commonly cited cost-effectiveness thresholds of between $50,000–150,000 per QALY.
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.